Title:Novel Antidiabetic Agents: Cardiovascular and Safety Outcomes
VOLUME: 26 ISSUE: 46
Author(s):Gerasimos Siasos*, Evanthia Bletsa, Panagiota K. Stampouloglou, Stavroula A. Paschou, Evangelos Oikonomou, Vasiliki Tsigkou, Alexios S. Antonopoulos, Manolis Vavuranakis and Dimitrios Tousoulis
Affiliation:First Department of Cardiology, “Hippokration” General Hospital, Medical School, National and Kapodistrian University of Athens, Athens, First Department of Cardiology, “Hippokration” General Hospital, Medical School, National and Kapodistrian University of Athens, Athens, First Department of Cardiology, “Hippokration” General Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Division of Endocrinology and Diabetes, “Aghia Sophia” Hospital, Medical School, National and Kapodistrian University of Athens, First Department of Cardiology, “Hippokration” General Hospital, Medical School, National and Kapodistrian University of Athens, Athens, First Department of Cardiology, “Hippokration” General Hospital, Medical School, National and Kapodistrian University of Athens, Athens, First Department of Cardiology, “Hippokration” General Hospital, Medical School, National and Kapodistrian University of Athens, Athens, First Department of Cardiology, “Hippokration” General Hospital, Medical School, National and Kapodistrian University of Athens, Athens, First Department of Cardiology, “Hippokration” General Hospital, Medical School, National and Kapodistrian University of Athens, Athens
Keywords:Antidiabetic agents, SGLT-2i, GLP1-RA, DPP-4i, cardiovascular disease, cardiovascular outcomes, cardiovascular safety, cardioprotection.
Abstract:Background: Concerns of elevated cardiovascular risk with some anti-diabetic medications warranted
trials on the cardiovascular outcome to demonstrate cardiovascular safety of newly marketed anti-diabetic
drugs. Although these trials were initially designed to evaluate safety, some of these demonstrated significant
cardiovascular benefits.
Purpose of Review: We reviewed the cardiovascular and safety outcomes of novel antidiabetic agents in patients
with type 2 diabetes and established cardiovascular disease or at high risk of it. We included the outcomes
of safety trials, randomized controlled trials, meta-analysis, large cohort studies, and real-world data, which
highlighted the cardiovascular profile of DPP-4is, GLP-1RAs and SGLT-2is.
Conclusion: Although DPP-4is demonstrated non-inferiority to placebo, gaining cardiovascular safety, as well
market authorization, SGLT-2is and most of the GLP-1RAs have shown impressive cardiovascular benefits in
patients with T2D and established CVD or at high risk of it. These favorable effects of novel antidiabetic agents
on cardiovascular parameters provide novel therapeutic approaches in medical management, risk stratification
and prevention.
